Evidence map›Paper›PMID 38733380›Full record

ArticleVirchows Archiv : an international journal of pathology2024

Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations.

Ben Davidson, Arild Holth, Kristina Lindemann, Ane Gerda Zahl Eriksson, Thale Andrea Nilsen, Annette Torgunrud

Abstract read
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Cancer of the ovary, fallopian tube, and peritoneum: 2025 update.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ben DavidsonDepartment of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310, Oslo, Norway. bend@medisin.uio.no.ORCID http://orcid.org/0000-0003-3332-8427
Arild HolthDepartment of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310, Oslo, Norway.
Kristina LindemannFaculty of Medicine, University of Oslo, Institute of Clinical Medicine, N-0316, Oslo, Norway.
Ane Gerda Zahl ErikssonFaculty of Medicine, University of Oslo, Institute of Clinical Medicine, N-0316, Oslo, Norway.
Thale Andrea NilsenDepartment of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310, Oslo, Norway.
Annette TorgunrudDepartment of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carcinosarcoma (CS) is an uncommon and clinically aggressive malignancy. The objective of the present study was to characterize the molecular features of CS at various anatomic locations, including serous effusions. Specimens (n = 32) consisted of 25 biopsies/surgical resection specimens and 7 serous effusions (6 peritoneal, 1 pleural) from 25 patients. Fresh-frozen cell pellets and surgical specimens underwent targeted next-generation sequencing covering 50 unique genes. A total of 31 mutations were found in 25 of the 32 tumors studied, of which 1 had 3 mutations, 4 had 2 different mutations, and 20 had a single mutation. The most common mutations were in TP53 (n = 25 in 24 tumors; 1 tumor with 2 different mutations), with less common mutations found in RB1 (n = 2), MET (n = 1), KRAS (n = 1), PTEN (n = 1), and KIT (n = 1). Patient-matched specimens harbored the same TP53 mutation. Tumors with no detected mutations were more common in serous effusion specimens (3/7; 43%) compared with surgical specimens (4/25; 16%). In conclusion, the molecular landscape of CS is dominated by TP53 mutations, reinforcing the observation that the majority of these tumors develop from high-grade serous carcinoma. Whether CS cells in serous effusions differ from their counterparts in solid lesions remains uncertain.

Indexed as

CarcinosarcomaMutationOvarian NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorDNA Mutational AnalysisFallopian Tube NeoplasmsFemaleHigh-Throughput Nucleotide SequencingHumansMiddle AgedTumor Suppressor Protein p53Biomarkers, TumorTP53 protein, humanTumor Suppressor Protein p53CarcinosarcomaEffusionSolid metastasisTargeted sequencingTP53

Identifiers

PMID38733380
PMCPMC11666747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.